Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine
Eric Tano, Stephanie San Martin, Stephen Girgis, Yadira Martinez-Fernandez, Carolina Sanchez Vegas
Abstract
On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakAuthorizationEmergency departmentPediatricsVirologyInternal medicineOutbreakDiseasePsychiatryInfectious disease (medical specialty)Computer scienceComputer securityViral Infections and Immunology ResearchHeparin-Induced Thrombocytopenia and ThrombosisSARS-CoV-2 and COVID-19 Research